Investors bid Emyria (ASX:EMD) up AU$18m despite increasing losses YoY, taking one-year return to 42%




  • In Business
  • 2022-08-16 23:16:45Z
  • By Simply Wall St.
 

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. To wit, the Emyria Limited (ASX:EMD) share price is 42% higher than it was a year ago, much better than the market decline of around 6.5% (not including dividends) in the same period. If it can keep that out-performance up over the long term, investors will do very well! Note that businesses generally develop over the long term, so the returns over the last year might not reflect a long term trend.

Since it's been a strong week for Emyria shareholders, let's have a look at trend of the longer term fundamentals.

Check out our latest analysis for Emyria

Emyria isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last year Emyria saw its revenue shrink by 6.7%. The stock is up 42% in that time, a fine performance given the revenue drop. To us that means that there isn't a lot of correlation between the past revenue performance and the share price, but a closer look at analyst forecasts and the bottom line may well explain a lot.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

Take a more thorough look at Emyria's financial health with this free report on its balance sheet.

A Different Perspective

Emyria shareholders should be happy with the total gain of 42% over the last twelve months. We regret to report that the share price is down 6.9% over ninety days. It may simply be that the share price got ahead of itself, although there may have been fundamental developments that are weighing on it. It's always interesting to track share price performance over the longer term. But to understand Emyria better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Emyria you should be aware of, and 1 of them makes us a bit uncomfortable.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

Does Renishaw (LON:RSW) Deserve A Spot On Your Watchlist?
Does Renishaw (LON:RSW) Deserve A Spot On Your Watchlist?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Mainfreight (NZSE:MFT) shareholders have earned a 24% CAGR over the last five years
Mainfreight (NZSE:MFT) shareholders have earned a 24% CAGR over the last five years

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...

Investors in AFT Pharmaceuticals (NZSE:AFT) have made a favorable return of 32% over the past five years
Investors in AFT Pharmaceuticals (NZSE:AFT) have made a favorable return of 32% over the past five years

AFT Pharmaceuticals Limited ( NZSE:AFT ) shareholders might be concerned after seeing the share price drop 13% in the...

Amidst increasing losses, Investors bid up Cytosorbents (NASDAQ:CTSO) 17% this past week
Amidst increasing losses, Investors bid up Cytosorbents (NASDAQ:CTSO) 17% this past week

This week we saw the Cytosorbents Corporation ( NASDAQ:CTSO ) share price climb by 17%. But that doesn't change the...

Investors in Optiva (TSE:OPT) have unfortunately lost 52% over the last five years
Investors in Optiva (TSE:OPT) have unfortunately lost 52% over the last five years

Generally speaking long term investing is the way to go. But no-one is immune from buying too high. To wit, the Optiva...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business